Covishield side effects in packaging: Serum Institute of India
In response to concerns over Covishield's side effects, the Serum Institute of India announced it ceased production and distribution of extra Covishield doses since December 2021 due to a notable decline in demand for prior vaccines. "We fully understand the ongoing concerns and it's crucial to emphasize our commitment to transparency and safety. From the outset, we have disclosed all rare to very rare side effects, including Thrombosis with Thrombocytopenia Syndrome, in the packaging insert in 2021," the SII spokesperson said.
